Crispr Theraptc (NASDAQ:CRSP) Director Kurt Von Emster sold 22,781 shares of the firm’s stock in a transaction dated Friday, August 25th. The stock was sold at an average price of $19.42, for a total transaction of $442,407.02. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Kurt Von Emster also recently made the following trade(s):

  • On Wednesday, August 23rd, Kurt Von Emster sold 17,989 shares of Crispr Theraptc stock. The stock was sold at an average price of $18.53, for a total transaction of $333,336.17.
  • On Monday, August 21st, Kurt Von Emster sold 3,150 shares of Crispr Theraptc stock. The stock was sold at an average price of $18.52, for a total transaction of $58,338.00.
  • On Thursday, August 17th, Kurt Von Emster sold 34,141 shares of Crispr Theraptc stock. The shares were sold at an average price of $19.06, for a total transaction of $650,727.46.
  • On Tuesday, August 15th, Kurt Von Emster sold 55,569 shares of Crispr Theraptc stock. The shares were sold at an average price of $19.59, for a total transaction of $1,088,596.71.
  • On Tuesday, August 8th, Kurt Von Emster sold 35,473 shares of Crispr Theraptc stock. The shares were sold at an average price of $18.63, for a total transaction of $660,861.99.
  • On Friday, August 4th, Kurt Von Emster sold 50,477 shares of Crispr Theraptc stock. The shares were sold at an average price of $17.81, for a total transaction of $898,995.37.
  • On Tuesday, August 1st, Kurt Von Emster sold 5,512 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.51, for a total transaction of $96,515.12.
  • On Friday, July 28th, Kurt Von Emster sold 41,312 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.63, for a total transaction of $728,330.56.
  • On Wednesday, July 26th, Kurt Von Emster sold 32,930 shares of Crispr Theraptc stock. The stock was sold at an average price of $17.60, for a total transaction of $579,568.00.
  • On Friday, July 14th, Kurt Von Emster sold 69,859 shares of Crispr Theraptc stock. The stock was sold at an average price of $16.84, for a total transaction of $1,176,425.56.

Crispr Theraptc (NASDAQ CRSP) traded up 0.97% on Monday, reaching $19.69. 566,493 shares of the company’s stock were exchanged. Crispr Theraptc has a 1-year low of $11.63 and a 1-year high of $25.00. The company’s market capitalization is $799.24 million. The company has a 50 day moving average price of $17.74 and a 200-day moving average price of $17.59.

Crispr Theraptc (NASDAQ:CRSP) last issued its earnings results on Thursday, August 10th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.62) by $0.06. Crispr Theraptc had a negative return on equity of 47.46% and a negative net margin of 406.61%. The company had revenue of $3.60 million for the quarter, compared to analyst estimates of $3.29 million. Crispr Theraptc’s revenue was up 350.0% on a year-over-year basis. On average, equities research analysts anticipate that Crispr Theraptc will post ($2.43) earnings per share for the current year.

ILLEGAL ACTIVITY NOTICE: This report was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.watchlistnews.com/insider-selling-crispr-theraptc-crsp-director-sells-22781-shares-of-stock/1528420.html.

Hedge funds and other institutional investors have recently modified their holdings of the company. Wellington Management Group LLP raised its position in shares of Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the last quarter. Credit Suisse AG purchased a new position in shares of Crispr Theraptc during the first quarter valued at $1,742,000. Paulson & CO. Inc. purchased a new position in shares of Crispr Theraptc during the first quarter valued at $1,099,000. Monashee Investment Management LLC raised its position in shares of Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the last quarter. Finally, Vanguard Group Inc. purchased a new position in shares of Crispr Theraptc during the second quarter valued at $273,000. 23.90% of the stock is currently owned by institutional investors.

A number of analysts recently commented on CRSP shares. Cann started coverage on shares of Crispr Theraptc in a research note on Monday, July 17th. They issued a “market perform” rating for the company. Chardan Capital restated a “buy” rating on shares of Crispr Theraptc in a research note on Monday, August 14th. SunTrust Banks, Inc. initiated coverage on shares of Crispr Theraptc in a research note on Thursday, July 13th. They issued a “hold” rating and a $16.00 target price for the company. Finally, Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research note on Tuesday, July 18th. Four research analysts have rated the stock with a hold rating and four have given a buy rating to the company’s stock. Crispr Theraptc has an average rating of “Buy” and a consensus target price of $21.92.

About Crispr Theraptc

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.

Insider Buying and Selling by Quarter for Crispr Theraptc (NASDAQ:CRSP)

Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with Analyst Ratings Network's FREE daily email newsletter.